[Federal Register Volume 70, Number 210 (Tuesday, November 1, 2005)]
[Notices]
[Pages 65901-65902]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-21672]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Statement of Organization, Functions, and Delegations of 
Authority

    Part C (Centers for Disease Control and Prevention) of the 
Statement of Organization, Functions, and Delegations of Authority of 
the Department of Health and Human Services (45 FR 67772-76, dated 
October 14, 1980, and corrected at 45 FR 69296, October 30, 1980, as 
amended most recently at 69 FR 77756, dated December 28, 2004) is 
amended to reorganize the National Center for HIV, STD, & TB 
Prevention.
    Section C-B, Organization and Functions, is hereby amended as 
follows:
    Delete in its entirety the following titles and functional 
statements: Division of AIDS, STD & TB Laboratory Research (CK7), 
Office of the Director (CK71), HIV, Immunology and Diagnostics Branch 
(CK72), HIV Immunology and Diagnostics Branch (CK73), Sexually 
Transmitted Infectious Diseases Branch (CK74), Tuberculosis/
Mycobacteriology Branch (CK75).
    Following the Training and Health Communication Branch (CK37), 
Division of STD Prevention (CK3), insert the following:
    Laboratory Reference and Research Branch, (CK38). (1) Performs 
research on the pathogenesis, genetics, and immunology of syphilis and 
other treponematoses, gonococcal and chlamydial infections, chancroid, 
genital herpes, donovanosis, bacterial vaginosis and trichomoniasis; 
(2) conducts and participates in clinical, field, and laboratory 
research to develop, evaluate, and improve laboratory methods used in 
the diagnosis and epidemiology of these sexually transmitted infections 
(STIs); (3) provides consultation and reference/diagnostic services for 
these STIs; (4) conducts laboratory-based surveillance for and research 
on the genetics of antimicrobial resistance in Neisseria gonorrhoeae; 
(5) serves as the WHO International Collaborating Center for Reference 
and Research in Syphilis Serology; and (6) provides consultation and 
laboratory support for international activities.
    Following the International Research and Programs Branch (CK47), 
Division of Tuberculosis Elimination (CK4), insert the following:
    Mycobacteriology Branch (HCK48). (1) Provides laboratory support 
for epidemic investigations, surveillance activities, and special 
studies of tuberculosis and other mycobacteria-caused diseases; (2) 
administers contracts to provide Mycobacterium tuberculosis genotyping, 
maintains a national database of genotypes, and conducts operational 
research to implement genotyping; (3) develops and evaluates new 
methods to subtype mycobacteria for epidemiologic studies; (4) serves 
as primary CDC focus for diagnostic mycobacteriology laboratory 
services and for laboratory aspects of nontuberculosis Mycobacterium 
species and of Hansen disease (leprosy); (5) administers grants and 
cooperative agreements with states and others to upgrade laboratory 
activities and provide special services; (6) provides reference 
diagnostic services, consultation, technical assistance, and training 
to State, Federal, and municipal public health laboratories; (7) 
provides laboratory support, reference services, assessment, 
consultation, and training for CDC's international tuberculosis 
activities; (8) develops, evaluates, or improves conventional and 
molecular methods for the detection, classification, identification, 
characterization, and susceptibility testing of mycobacteria and 
mycobacteria-caused diseases; (9) conducts studies to define the role 
of bacterial virulence factors, host factors, and pathogenic and 
immunologic mechanisms in disease processes and protective immunity and 
develops, evaluates, and improves immunologic methods for the diagnosis 
and prevention of mycobacteria-caused diseases; (10) develops tissue 
culture and animal models of mycobacteria-caused diseases and conducts 
studies on chemotherapy, immunotherapy, pathogenesis, pathology, and 
vaccines for mycobacteria-caused diseases; (11) conducts studies on the 
isolation, taxonomy, and ecology of mycobacteria and develops tests to 
identify new species; (12) conducts and supports studies to 
characterize newly emerging pathogenic species of Mycobacterium and 
associated diseases.
    Following the HIV Incidence and Case Surveillance Branch (CK56), 
Division of HIV, AIDS Prevention--Surveillance and Epidemiology (CK5), 
insert the following:
    HIV and Retrovirology Laboratory Branch (HCK57). (1) Conducts 
studies of human immunodeficiency viruses (HIVs) and other human and 
zoonotic retroviruses, including the diseases they cause, their modes 
of transmission, and the means for their control through virus 
detection, isolation, and characterization by virologic, molecular, and 
cellular biologic methods; (2)

[[Page 65902]]

collaborates with NCHSTP investigators to conduct HIV epidemiologic and 
surveillance studies worldwide particularly as they pertain to 
prevention and intervention strategies; (3) identifies and 
characterizes new HIV isolates and develops new screening tests for 
these isolates to determine their prevalence in various populations; 
(4) determines geotypic and phenotypic variations of HIVs that may 
affect pathogenesis, drug resistance, persistence, virulence, and 
transmissibility; (5) conducts and supports field epidemiologic 
investigations of the prevalence, distribution, trends, and risk 
factors associated with non-AIDS retroviral infections and associated 
diseases; (6) serves as a World Health Organization (WHO) Reference 
Center and as a member of the UNAIDS Virus Network to provide 
international consultation and technical assistance on laboratory 
procedures for HIV isolation, detection, and characterization; (7) 
develops and evaluates procedures for the isolation and 
characterization of HIV and for the detection of retroviral DNA or RNA 
from clinical samples; (8) provides training, reference testing, and 
reference reagents for virologic and molecular characterization of 
divergent HIVs for public health laboratories in the United States and 
WHO; (9) serves as a reference laboratory for the isolation of zoonotic 
retroviruses from clinical samples; (10) develops collaborations with 
other CDC and non-CDC scientists to promote scientific progress and 
accomplishments; and (11) collaborates with industry to promote 
commercialization of useful technology, methodologies, and reagents of 
public health importance.
    HIV Immunology and Diagnostic Laboratory Branch (HCK58). (1) 
Conducts basic and applied studies of microbial-host interactions that 
occur in infections, particularly infection with human immunodeficiency 
virus (HIV); (2) conducts basic and applied investigations of the 
immune cell interactions that occur in HIV infection as well as in 
related immunologic/infectious diseases; conducts investigations of 
genetic traits of the host that influence the susceptibility, disease 
course, and immune response to infectious disease, particularly HIV 
diseases; (3) conducts studies related to the development, evaluation, 
improvement, and standardization of laboratory technologies uses for 
the diagnosis, surveillance, and monitoring of HIV infection both 
independently and in collaboration with the biotechnology industry; (4) 
performs HIV antigen and antibody testing plus related standardized 
assays in support of the diagnostic/surveillance/epidemiologic 
requirements of CDC-based and CDC-affiliated studies of the HIV 
epidemic; (5) serves as a reference laboratory for State and local 
health departments; and (6) provides diagnostic services to other 
Federal agencies, the World Health Organization, CDC-affiliated 
academic centers, CDC-affiliated studies with other countries, and 
community organizations, as appropriate.

    Dated: April 1, 2005.
William H. Gimson,
Chief Operating Officer, Centers for Disease Control and Prevention 
(CDC).
[FR Doc. 05-21672 Filed 10-31-05; 8:45 am]
BILLING CODE 4160-18-M